Study of the Safety and Immunogenicity of Reduced Doses of the US Yellow Fever Vaccine
An Exploratory, Pilot Study of the Safety and Immunogenicity of Reduced Doses of the US Yellow Fever Vaccine
Sponsor: US Army Medical Research Institute of Infectious Diseases
This PHASE4 trial investigates Yellow Fever Vaccination Reaction and is currently completed. US Army Medical Research Institute of Infectious Diseases leads this study, which shows 4 recorded versions since 2021 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
4 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE4
-
Sep 2023 — Jul 2024 [monthly]
Completed PHASE4
Status: Active Not Recruiting → Completed
-
Jun 2022 — Sep 2023 [monthly]
Active Not Recruiting PHASE4
First recorded
Jun 2021
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- US Army Medical Research Institute of Infectious Diseases
For direct contact, visit the study record on ClinicalTrials.gov .